Search results for Farletuzumab

Farletuzumab Biosimilar – Anti-FOLR1 mAb – Research Grade, ProteoGenix, PX-TA1207

Description of Farletuzumab Biosimilar - Anti-FOLR1 mAb - Research Grade The Structure of Farletuzumab Biosimilar – Anti-FOLR1 mAb Farletuzumab Biosimilar, also known as Anti-FOLR1 monoclonal antibody (mAb), is a therapeutic antibody that specifically targets the folate receptor alpha (FOLR1) protein. It is a biosimilar version of the original Farletuzumab, which has been developed to have the same structure and function as the original antibody. The structure of Farletuzumab Biosimilar is similar to other monoclonal antibodies, consisting of two heavy chains and two light chains that are connected by disulfide bonds. The heavy chains are around 50 kDa in size and the light chains are around 25 kDa, resulting in a total molecular weight of approximately 150 kDa. The variable regions of the heavy and light chains are responsible for the specificity of Farletuzumab Biosimilar, as they contain the antigen-binding sites that recognize and bind to the FOLR1 protein. The constant regions of the antibody are responsible for mediating the effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The Activity of Farletuzumab Biosimilar – Anti-FOLR1 mAb The main activity of Farletuzumab Biosimilar is to bind to the FOLR1 protein, which is overexpressed in various types of cancer cells. This binding leads to the inhibition of cancer cell growth and survival, making Farletuzumab Biosimilar a promising therapeutic agent for the treatment of cancer. In addition to its direct anti-tumor activity, Farletuzumab Biosimilar also has the ability to activate the immune system through its effector functions. This can enhance the body’s natural defense mechanisms against cancer cells, leading to a more effective and targeted treatment approach. Studies have shown that Farletuzumab Biosimilar has a high affinity and specificity for FOLR1, making it a potent and selective therapeutic agent. It has also been shown to have low immunogenicity, meaning it is less likely to cause an immune response in patients. The Application of Farletuzumab Biosimilar – Anti-FOLR1 mAb Farletuzumab Biosimilar is currently being investigated as a potential treatment for various types of cancer, including ovarian, lung, and breast cancer. It is typically used in combination with other cancer therapies, such as chemotherapy, to enhance its anti-tumor effects. One of the main advantages of Farletuzumab Biosimilar is its biosimilarity to the original Farletuzumab, which has already been extensively studied in clinical trials. This allows for a faster and more streamlined development process, potentially leading to quicker availability of this therapeutic option for cancer patients. In addition to its potential as a cancer treatment, Farletuzumab Biosimilar is also being explored as a diagnostic tool. Due to its high specificity for FOLR1, it can be used to detect the presence of FOLR1 in cancer cells, allowing for more accurate and targeted diagnosis of certain types of cancer. In conclusion, Farletuzumab Biosimilar – Anti-FOLR1 mAb is a promising therapeutic option for the treatment of cancer. Its specific structure and activity make it a potent and selective agent, with the potential to enhance the body’s natural defense mechanisms against cancer cells. With ongoing research and clinical trials, Farletuzumab Biosimilar may soon become a valuable addition to the arsenal of cancer treatments.

Farletuzumab, Kyinno, KB-1332

Farletuzumab, Abbexa, abx831164

Farletuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting FOLR1, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Farletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.

Farletuzumab ELISA Kit, ProteoGenix, KPTX185

Description of Farletuzumab ELISA Kit Introduction to Farletuzumab ELISA Kit Farletuzumab is a humanized monoclonal antibody that specifically targets the folate receptor alpha (FRα). This receptor is overexpressed in a variety of solid tumors, making it a promising therapeutic target for cancer treatment. The Farletuzumab ELISA Kit is a powerful tool for detecting and quantifying this antibody in biological samples. In this article, we will discuss the structure, activity, and application of the Farletuzumab ELISA Kit. Structure of Farletuzumab ELISA Kit The Farletuzumab ELISA Kit is composed of several components, including a microplate coated with FRα antigen, a standard solution of known concentration of Farletuzumab, and detection reagents. The microplate is typically made of polystyrene and is divided into multiple wells, each of which can accommodate a small volume of the sample. The FRα antigen is immobilized on the surface of the microplate, allowing for specific binding of Farletuzumab. Activity of Farletuzumab ELISA Kit The activity of the Farletuzumab ELISA Kit is based on the principle of enzyme-linked immunosorbent assay (ELISA). This technique utilizes the specific binding of an antibody to its target antigen, which is then detected using an enzyme-linked secondary antibody. In the case of the Farletuzumab ELISA Kit, the primary antibody is Farletuzumab and the secondary antibody is conjugated to an enzyme such as horseradish peroxidase (HRP). When the sample is added to the microplate, any Farletuzumab present in the sample will bind to the FRα antigen on the plate. The addition of the HRP-conjugated secondary antibody and a substrate for the enzyme will result in a color change, which can be measured using a spectrophotometer. The intensity of the color is directly proportional to the amount of Farletuzumab present in the sample, allowing for accurate quantification. Application of Farletuzumab ELISA Kit The Farletuzumab ELISA Kit has a wide range of applications in both research and clinical settings. It is commonly used to measure the levels of Farletuzumab in serum, plasma, and other biological samples. This can provide valuable information about the pharmacokinetics and pharmacodynamics of the antibody, as well as its potential efficacy as a therapeutic agent. Additionally, the Farletuzumab ELISA Kit can be used to monitor the response of patients to Farletuzumab treatment, as well as to assess the presence of anti-drug antibodies that may affect treatment efficacy. Furthermore, the Farletuzumab ELISA Kit can also be used in the development of new therapeutic agents targeting FRα. By measuring the binding affinity and specificity of potential drugs to FRα using the Farletuzumab ELISA Kit, researchers can identify promising candidates for further development. Conclusion In summary, the Farletuzumab ELISA Kit is a valuable tool for detecting and quantifying Farletuzumab, a promising therapeutic antibody targeting FRα. Its structure, activity, and application make it an essential component in the development and evaluation of Farletuzumab-based therapies. With its high sensitivity and specificity, the Farletuzumab ELISA Kit is a crucial asset in the fight against cancer and the search for new and effective treatments.

Farletuzumab ELISA Kit, Abbexa, abx395074

Farletuzumab ELISA Kit is a quantitative ELISA kit for detection of Farletuzumab.Farletuzumab (MORAb-003) is a humanized α-FR-targeted monoclonal antibody derived from the murine antibody, LK26 (Teng, Xie, Teng, & Lee, 2012). In preclinical studies, farletuzumab elicited robust antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, thus inhibiting the growth of human ovarian tumor xenografts (Teng et al., 2012). Farletuzumab combined with carboplatin and taxane may enhance the response rate and duration of response in patients with platinum-sensitive ovarian cancer with first relapse after remission duration of 6–18 months (Konner et al., 2010). Based on these encouraging findings, a Phase III study was undertaken in patients with platinum-sensitive recurrent ovarian cancer (Walters et al., 2013). The FAR131 trial did not prove efficacy for patients with platinum-sensitive ovarian cancer (PSOC, defined as a PFI of ≥ 6 months), in terms of the primary endpoint of PFS. Aside from Farletuzumab, other antibodies have been developed to target FR, and tested clinically. Similar to studies exploiting Vintafolide, a Phase III, open-label, randomized study (ClinicalTrials.gov Identifier: NCT02631876) was designed to compare the safety and efficacy of Mirvetuximab soravtansine, also known as IMGN853, an α-FR-targeting antibody-drug conjugate, to that of selected single-agent chemotherapies in women with platinum-resistant α-FR-positive advanced EOC, and other pelvic cancers. The antibody serves to specifically target the highly potent microtubule inhibitor maytansinoid DM4 to the α-FR-positive cancer cells. In addition, vaccines against FR have been produced and evaluated, such as the folate-binding protein vaccines E39 and J65 involved in the Phase Ib trial (ClinicalTrials.gov Identifier: NCT02019524) for patients with breast or ovarian cancer diagnosis who have been treated and are without evidence of disease. A Phase II clinical trial (NCT02764333) is testing on patients with Pt-resistant ovarian cancer the safety and effectiveness of two investigational drugs, TPIV200/huFR-1 (also called TPIV200), a vaccine consisting of proteins from α-FR mixed with GM-CSF, and durvalumab (MEDI4736).

Farletuzumab Biosimilar - Research Grade, ichor.bio, ICH5114

Detects human FOLR1

Farletuzumab Vedotin Biosimilar - Research Grade, ichor.bio, ICH5114V